Comparing Mavenclad vs Ocrevus
Mavenclad | Ocrevus |
|
---|
Mavenclad (cladribine) | Ocrevus (ocrelizumab) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Mavenclad may be given to people with relapsing forms of MS who have had an inadequate response to, or who are unable to tolerate other medications for MS that have a more favorable safety profile... View more |
Prescription only
Ocrevus is a CD20 monoclonal antibody that causes B-cells to self-destruct or disintegrate, reducing inflammation in people with MS. After an initial loading dose, it is given by IV infusion every... View more |
Related suggestions Popular comparisons
|
|||||||||||||||
More about Mavenclad (cladribine) | More about Ocrevus (ocrelizumab) | ||||||||||||||||
Ratings & Reviews | |||||||||||||||||
Mavenclad has an average rating of 9.7 out of 10 from a total of 4 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Ocrevus has an average rating of 4.9 out of 10 from a total of 162 ratings on Drugs.com. 37% of reviewers reported a positive effect, while 49% reported a negative effect. |
||||||||||||||||
Drug Class | |||||||||||||||||
Side Effects | |||||||||||||||||
See also: Mavenclad side effects in more detail. |
See also: Ocrevus side effects in more detail. |
||||||||||||||||
Generic Availability | |||||||||||||||||
N/A |
|||||||||||||||||
Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Mavenclad prices |
View all Ocrevus prices |
||||||||||||||||
Dosage Form(s) Available | |||||||||||||||||
|
|
||||||||||||||||
Brand Names | |||||||||||||||||
Other cladribine brands include: Cladribine Novaplus |
N/A |
||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | |||||||||||||||||
6.7 hours |
624 hours |
||||||||||||||||
CSA Schedule ** View glossary of terms | |||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | |||||||||||||||||
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | |||||||||||||||||
A total of 489 drugs are known to interact with Mavenclad:
|
A total of 406 drugs are known to interact with Ocrevus:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
Disease Interactions | |||||||||||||||||
First Approval Date | |||||||||||||||||
March 29, 2019 |
March 28, 2017 |
||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | |||||||||||||||||
N/A |
N/A |
||||||||||||||||
More Information | |||||||||||||||||
Patient resources | |||||||||||||||||
Professional Resources | |||||||||||||||||
Related Treatment Guide | |||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.